Live news related to VALNEVA stock (FR0004056851): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Trading volumes remain moderate with 0.38% of capital exchanged.
Valneva SE has announced the final results of a Phase 2 study on its chikungunya vaccine, IXCHIQ®, demonstrating a robust immune response and good tol…
The stock of the Franco-Austrian biotech specializing in vaccines shows a significant decline this Friday, November 28, at midday.
Valneva's stock closed on Thursday, November 27 at 4.30 euros, up by 5.5% from the previous day. This surge followed the announcement on Wednesday of …
Valneva SE has reported favorable final data on the immunogenicity and safety of its Lyme disease vaccine candidate, VLA15, following a Phase 2 study.
This morning, the biopharmaceutical company Valneva unveiled encouraging final data for its Lyme disease vaccine candidate, VLA15, from a Phase 2 stud…
Valneva's stock is up by 3.32% this Thursday, November 13, at midday, trading at 4.044 euros compared to 3.91 euros the previous day. Trading volumes …
